Genetic Screening of Epigenetic Modifiers in Newly Diagnosed Breast Cancer Patients.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- 1) Outcome measures used in this research comprise of demographic and clinical data, histopathology and diagnostic tests reports and descriptions of various treatment regimens used.
研究概览
简要总结
In our study, we intend to collect the normal and cancerous breast tissue samples of newly diagnosed breast cancer patients and record the associated demographic and clinical details. The mRNA expression of UBL5, EZH2 and UHRF1 will be studied using these samples. We will also be analyzing the correlation between mRNA expression with clinicopathological characteristics of the patients.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- Female
入选标准
- •Newly diagnosed female breast cancer patients
- •Patients scheduled for Modified Radical Mastectomy (MRM) or Breast Conservative Surgery (BCS).
- •Patients who are willing to give informed consent.
- •Patients above the age of 18 years.
排除标准
- •Vulnerable patients
- •HIV, TB, Hepatitis positive patients.
结局指标
主要结局
1) Outcome measures used in this research comprise of demographic and clinical data, histopathology and diagnostic tests reports and descriptions of various treatment regimens used.
时间窗: 3 Years
2) mRNA expressions of UHRF1
时间窗: 3 Years
3) mRNA expressions of EZH2
时间窗: 3 Years
4) mRNA expressions of UBL5
时间窗: 3 Years
次要结局
- Correlating sociodemographic and clinicopathological parameters with the mRNA expressions of UHRF1, EZH2 and UBL5.(3 Years)
研究者
Dr Mahadev Rao
Manipal College of Pharmaceutical Sciences, MAHE, Manipal